Rwanda is currently facing its first outbreak of the deadly Marburg virus, which has resulted in 11 confirmed deaths as health officials investigate the source of the infection. The outbreak has prompted a health alert, with health authorities and the World Health Organization expressing concern over the potential for international spread. In response, Rwanda is set to initiate vaccine trials in the coming weeks, and measures have been implemented to restrict funeral sizes to contain the virus. Gilead has pledged to donate antiviral treatments to aid in the response. With symptoms resembling those of Ebola and a mortality rate of up to 90%, the situation remains critical as public health officials continue to monitor dozens of reported cases.